Voxelotor versus other therapeutic options for sickle cell disease: Are we still lagging behind in treating the disease?

BACKGROUND: Sickle cell disease (SCD) is one of the most prevalent hemoglobinopathies that affects around 275,000 neonates annually. Until 2017, hydroxyurea was the only available drug for SCD treatment. Later on, L‐glutamine and crizanlizumab have shown promising results in SCD therapy. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Tayyaba Rehan, Syeda, Hussain, Hassan ul, Malik, Farheen, Usama, Rana Muhammad, Tahir, Muhammad Junaid, Asghar, Muhammad Sohaib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213830/
https://www.ncbi.nlm.nih.gov/pubmed/35774831
http://dx.doi.org/10.1002/hsr2.713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213830/
https://www.ncbi.nlm.nih.gov/pubmed/35774831
http://dx.doi.org/10.1002/hsr2.713

Ejemplares similares